European Union Drugs Agency (EUDA)

@EUDrugsAgency · Lisbon, Portugal · joined 25 Jun 2009

The EUDA is your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations.

21 621Followers

395Following

6 440Posts total

3.1KViews on collected posts

Son gönderiler

European Union Drugs Agency (EUDA)@EUDrugsAgency3 Sep

📢 There's still time to register! Join our webinar on dual disorders and hear the latest evidence, key insights from the EUDA miniguide, and examples of approaches to improving access to integrated care. 📅 9 September 2026 💻 Secure your place: https://t.co/6E5QNAsUhG 453 views · 5 likes · 2 reposts · 0 replies Open on X →

European Union Drugs Agency (EUDA)@EUDrugsAgency3 Sep

🇲🇩 Today, the EUDA and the Republic of Moldova signed a Working Arrangement to enhance cooperation on drug monitoring, early warning, preparedness, health and social responses and legislation. 🔎 Read more here: https://t.co/zNpv1rEMKN https://t.co/RgPbD3bFnK 345 views · 6 likes · 0 reposts · 0 replies Open on X →

European Union Drugs Agency (EUDA)@EUDrugsAgency1 Sep

👥 How is the European drug situation perceived from institutional and civil society perspectives? Join our webinar to hear experts from the EUDA and civil society organisations exchange views on the latest developments. 📅 30 September 2026 💻 https://t.co/0ZTSW51vzg https://t.c 415 views · 3 likes · 0 reposts · 0 replies Open on X →

European Union Drugs Agency (EUDA)@EUDrugsAgency1 Sep

🎒 Kids are back in school. But what’s changed in the schoolyard? 110k teens across 37 European countries took part in our latest survey. 🌿 Cannabis use is at its lowest 🍺 They are drinking less than ever 🚬 Smoking has halved, but vaping is rising 👀 https://t.co/SWQbScjOVW http 542 views · 6 likes · 5 reposts · 0 replies Open on X →

European Union Drugs Agency (EUDA)@EUDrugsAgency31 Aug

📰 The August issue of Drugnet Europe is out! 🔍 Explore the latest developments from the EUDA: https://t.co/d4fiqzLoRB 📩 Subscribe to Drugnet Europe: https://t.co/XvuSEwqghh https://t.co/NfSt9wPde8 491 views · 4 likes · 1 reposts · 0 replies Open on X →

European Union Drugs Agency (EUDA)@EUDrugsAgency15 Jul

🧩 Mental health and substance use disorders often occur together, creating complex challenges for individuals, services and healthcare systems. Join our webinar on #DualDisorders to explore the latest evidence: https://t.co/6E5QNAsUhG 📅 9 September #MentalHealth https://t.co/ 844 views · 1 likes · 1 reposts · 0 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 5 gönderi, 10K–100K takipçi aralığıyla yan yana. aynı büyüklükteki hesaplardan daha az kişiye ulaşıyor.

Medyan görüntülenme453bu hesap92410K–100K için medyan

Erişim, %2.10%bu hesap3.62%10K–100K için medyan

Etkileşim, %1.54%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	453	924	0.49×
Erişim (görüntülenme ÷ takipçi)	2.10%	3.62%	0.58×
Etkileşim oranı	1.54%	1.52%	1.02×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

84415 Jul

49131 Aug

5421 Sep

415

3453 Sep

453

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.36%15 Jul

1.02%31 Aug

2.03%1 Sep

0.72%

1.74%3 Sep

1.55%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes67.6%25 in total

Reposts24.3%9 in total

Quotes2.7%1 in total

Bookmarks5.4%2 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.